CN104592388A - 一种抗人Tim-3的单克隆抗体的抗原结合部分 - Google Patents
一种抗人Tim-3的单克隆抗体的抗原结合部分 Download PDFInfo
- Publication number
- CN104592388A CN104592388A CN201510093149.3A CN201510093149A CN104592388A CN 104592388 A CN104592388 A CN 104592388A CN 201510093149 A CN201510093149 A CN 201510093149A CN 104592388 A CN104592388 A CN 104592388A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- tim
- antigen
- cell
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 title claims abstract description 109
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 title claims abstract description 107
- 230000027455 binding Effects 0.000 title claims abstract description 47
- 239000000427 antigen Substances 0.000 title claims abstract description 46
- 108091007433 antigens Proteins 0.000 title claims abstract description 46
- 102000036639 antigens Human genes 0.000 title claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000008093 supporting effect Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 abstract description 36
- 239000003814 drug Substances 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 102000049109 human HAVCR2 Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 97
- 108090000623 proteins and genes Proteins 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 239000012980 RPMI-1640 medium Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 8
- 235000011130 ammonium sulphate Nutrition 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 230000024835 cytogamy Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 101150022210 tim gene Proteins 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 239000000120 Artificial Saliva Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 101710123661 Venom allergen 5 Proteins 0.000 description 2
- XOCUXOWLYLLJLV-UHFFFAOYSA-N [O].[S] Chemical compound [O].[S] XOCUXOWLYLLJLV-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001915 nurse cell Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108010028349 saliva Orthana Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 241000228232 Aspergillus tubingensis Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710197064 Lectin 9 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510093149.3A CN104592388B (zh) | 2015-03-02 | 2015-03-02 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510093149.3A CN104592388B (zh) | 2015-03-02 | 2015-03-02 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104592388A true CN104592388A (zh) | 2015-05-06 |
CN104592388B CN104592388B (zh) | 2017-05-31 |
Family
ID=53118477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510093149.3A Expired - Fee Related CN104592388B (zh) | 2015-03-02 | 2015-03-02 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104592388B (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016068803A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
WO2016068802A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
CN105785051A (zh) * | 2016-05-05 | 2016-07-20 | 中国人民解放军军事医学科学院基础医学研究所 | 血清中可溶性Tim-3蛋白作为诊断慢性肾病的标志物 |
CN106632675A (zh) * | 2016-12-15 | 2017-05-10 | 常州格露康生物医药科技有限公司 | 一种抗人Tim‑3单克隆抗体8E11及其制备方法 |
CN107132357A (zh) * | 2017-03-23 | 2017-09-05 | 山东大学 | 一种逆转乙型肝炎病毒慢性感染的抗Tim‑3抗体和α‑galcer的组合及应用 |
CN107400165A (zh) * | 2016-05-18 | 2017-11-28 | 上海开拓者生物医药有限公司 | 一种il‑13抗体及其制备方法和应用 |
CN108101989A (zh) * | 2016-11-24 | 2018-06-01 | 复旦大学 | 针对人tim-3的全人源单域抗体及应用 |
CN108245685A (zh) * | 2018-01-11 | 2018-07-06 | 广西壮族自治区人民医院 | 基于TIM蛋白和IgG蛋白的融合蛋白的防治变应性疾病的药物及其制备方法 |
US10077306B2 (en) | 2016-07-14 | 2018-09-18 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
CN108794630A (zh) * | 2017-12-18 | 2018-11-13 | 镇江爱必梦生物科技有限公司 | 鼠抗人tim3蛋白单克隆抗体制备及其免疫组化用途 |
CN108948193A (zh) * | 2017-05-18 | 2018-12-07 | 珠海市丽珠单抗生物技术有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
WO2019046321A1 (en) | 2017-08-28 | 2019-03-07 | Bristol-Myers Squibb Company | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS |
CN109476751A (zh) * | 2016-05-27 | 2019-03-15 | 艾吉纳斯公司 | 抗tim-3抗体及其使用方法 |
CN109563172A (zh) * | 2016-08-25 | 2019-04-02 | 伊莱利利公司 | 抗tim-3抗体 |
CN109983032A (zh) * | 2017-02-27 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | Tim-3抗体、其抗原结合片段及医药用途 |
CN110144011A (zh) * | 2018-02-14 | 2019-08-20 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
WO2019174637A1 (zh) * | 2018-03-15 | 2019-09-19 | 珠海市丽珠单抗生物技术有限公司 | 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途 |
CN110305216A (zh) * | 2018-03-20 | 2019-10-08 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
CN111253489A (zh) * | 2019-07-05 | 2020-06-09 | 石河子大学 | 一种tim-3纳米抗体、制备方法及其应用 |
CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
WO2021051351A1 (zh) * | 2019-09-19 | 2021-03-25 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
CN113164601A (zh) * | 2019-09-19 | 2021-07-23 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1902227A (zh) * | 2003-10-03 | 2007-01-24 | 布赖汉姆妇女医院 | Tim-3配体及其方法 |
CN103936853A (zh) * | 2014-01-26 | 2014-07-23 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
CN104072615A (zh) * | 2014-01-26 | 2014-10-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 |
-
2015
- 2015-03-02 CN CN201510093149.3A patent/CN104592388B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1902227A (zh) * | 2003-10-03 | 2007-01-24 | 布赖汉姆妇女医院 | Tim-3配体及其方法 |
CN103936853A (zh) * | 2014-01-26 | 2014-07-23 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
CN104072615A (zh) * | 2014-01-26 | 2014-10-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10435466B2 (en) | 2014-10-27 | 2019-10-08 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
WO2016068802A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
US10259874B2 (en) | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
US11142574B2 (en) | 2014-10-27 | 2021-10-12 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
WO2016068803A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
CN105785051A (zh) * | 2016-05-05 | 2016-07-20 | 中国人民解放军军事医学科学院基础医学研究所 | 血清中可溶性Tim-3蛋白作为诊断慢性肾病的标志物 |
CN105785051B (zh) * | 2016-05-05 | 2017-05-31 | 中国人民解放军军事医学科学院基础医学研究所 | 血清中可溶性Tim‑3蛋白作为诊断慢性肾病的标志物 |
CN107400165A (zh) * | 2016-05-18 | 2017-11-28 | 上海开拓者生物医药有限公司 | 一种il‑13抗体及其制备方法和应用 |
US11839653B2 (en) | 2016-05-27 | 2023-12-12 | Agenus Inc. | Anti-TIM-3 antibodies and methods of use thereof |
CN109476751A (zh) * | 2016-05-27 | 2019-03-15 | 艾吉纳斯公司 | 抗tim-3抗体及其使用方法 |
CN109476751B (zh) * | 2016-05-27 | 2024-04-19 | 艾吉纳斯公司 | 抗tim-3抗体及其使用方法 |
US11591392B2 (en) | 2016-07-14 | 2023-02-28 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US10077306B2 (en) | 2016-07-14 | 2018-09-18 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US10533052B2 (en) | 2016-07-14 | 2020-01-14 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
CN109563172A (zh) * | 2016-08-25 | 2019-04-02 | 伊莱利利公司 | 抗tim-3抗体 |
CN108101989A (zh) * | 2016-11-24 | 2018-06-01 | 复旦大学 | 针对人tim-3的全人源单域抗体及应用 |
CN106632675A (zh) * | 2016-12-15 | 2017-05-10 | 常州格露康生物医药科技有限公司 | 一种抗人Tim‑3单克隆抗体8E11及其制备方法 |
CN109983032A (zh) * | 2017-02-27 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | Tim-3抗体、其抗原结合片段及医药用途 |
CN109983032B (zh) * | 2017-02-27 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Tim-3抗体、其抗原结合片段及医药用途 |
CN107132357B (zh) * | 2017-03-23 | 2019-11-01 | 山东大学 | 一种逆转乙型肝炎病毒慢性感染的抗Tim-3抗体和α-galcer的组合及应用 |
CN107132357A (zh) * | 2017-03-23 | 2017-09-05 | 山东大学 | 一种逆转乙型肝炎病毒慢性感染的抗Tim‑3抗体和α‑galcer的组合及应用 |
CN108948193A (zh) * | 2017-05-18 | 2018-12-07 | 珠海市丽珠单抗生物技术有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
CN108948193B (zh) * | 2017-05-18 | 2022-12-09 | 上海健信生物医药科技有限公司 | 针对tim-3的抗体分子,抗原结合片段及其医药用途 |
WO2019046321A1 (en) | 2017-08-28 | 2019-03-07 | Bristol-Myers Squibb Company | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS |
CN108794630A (zh) * | 2017-12-18 | 2018-11-13 | 镇江爱必梦生物科技有限公司 | 鼠抗人tim3蛋白单克隆抗体制备及其免疫组化用途 |
CN108245685A (zh) * | 2018-01-11 | 2018-07-06 | 广西壮族自治区人民医院 | 基于TIM蛋白和IgG蛋白的融合蛋白的防治变应性疾病的药物及其制备方法 |
CN110144011A (zh) * | 2018-02-14 | 2019-08-20 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
CN110144011B (zh) * | 2018-02-14 | 2020-06-23 | 上海洛启生物医药技术有限公司 | 针对t淋巴细胞免疫球蛋白黏蛋白3的单域抗体 |
WO2019174637A1 (zh) * | 2018-03-15 | 2019-09-19 | 珠海市丽珠单抗生物技术有限公司 | 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途 |
CN110305216A (zh) * | 2018-03-20 | 2019-10-08 | 无锡智康弘义生物科技有限公司 | 新型抗tim-3抗体 |
CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
CN111253489B (zh) * | 2019-07-05 | 2023-08-01 | 石河子大学 | 一种tim-3纳米抗体、制备方法及其应用 |
CN111253489A (zh) * | 2019-07-05 | 2020-06-09 | 石河子大学 | 一种tim-3纳米抗体、制备方法及其应用 |
CN113166264A (zh) * | 2019-09-19 | 2021-07-23 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
CN113164601A (zh) * | 2019-09-19 | 2021-07-23 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
WO2021051351A1 (zh) * | 2019-09-19 | 2021-03-25 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
CN113164601B (zh) * | 2019-09-19 | 2023-09-29 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
CN113166264B (zh) * | 2019-09-19 | 2024-02-27 | 上药生物治疗(香港)有限公司 | 一种分离的抗原结合蛋白及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104592388B (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104592388A (zh) | 一种抗人Tim-3的单克隆抗体的抗原结合部分 | |
CN102492038B (zh) | 抗人Tim-3的中和性单克隆抗体L3D及其用途 | |
CN1984672B (zh) | Nkg2d的调节 | |
CN103936853B (zh) | 一种检测tim-3试剂盒及其使用方法 | |
JP6753946B2 (ja) | 抗人pd−1人源化単クローン抗体及び応用 | |
CN104220456B (zh) | 结合并阻断髓样细胞表达的触发受体‑1 (trem‑1)的抗体 | |
CN102659945B (zh) | 抗C5aR抗体及其应用 | |
CN105669864B (zh) | 抗人程序性死亡受体1抗体及其制备方法和用途 | |
CN107660150A (zh) | Il‑18结合蛋白(il‑18bp)和抗体在炎性疾病中 | |
CN110272490A (zh) | 靶向ctla-4抗体、其制备方法和用途 | |
CN110352073A (zh) | 针对timp-2的抗体用于改善肾功能的用途 | |
CN107043420B (zh) | 一种抗pd-1抗体及其应用 | |
CN102281898B (zh) | Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 | |
CN1970573B (zh) | 一种抗蓖麻毒素的中和性单克隆抗体3e1,其制备方法和用途 | |
CN102548573A (zh) | Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 | |
TW200846362A (en) | A polyclonal antibody product | |
CN104379165B (zh) | 炎症疾病治疗剂 | |
CN106188298B (zh) | 一种Vsig4纳米抗体及其抗原表位鉴定方法和应用 | |
CN107964045A (zh) | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 | |
BR112020025504A2 (pt) | Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido | |
WO2023046097A1 (zh) | 抗tigit人源化抗体或其抗原结合片段及其应用 | |
CN107849134A (zh) | 用抗ccr4抗体介导细胞因子表达的方法 | |
CN103665164A (zh) | 一种检测Tim-3的ELISA试剂盒 | |
CN110511277A (zh) | 一种抗hsp90单克隆抗体及其应用 | |
CN108840932A (zh) | 一种pd-1特异性抗体及其抗肿瘤应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Kang Chunyan Inventor after: Xiao Yan Inventor after: Liu Changting Inventor after: Fang Xiangqun Inventor after: Qu Baolin Inventor after: Li Hongxia Inventor after: Su Maosheng Inventor after: Zhao Yongsheng Inventor after: Cai Boning Inventor before: Kang Chunyan Inventor before: Jiang Xingwei Inventor before: Han Gencheng Inventor before: Xiao Yan Inventor before: Liu Changting Inventor before: Fang Xiangqun Inventor before: Qu Baolin Inventor before: Li Hongxia Inventor before: Su Maosheng Inventor before: Zhao Yongsheng Inventor before: Cai Boning |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170531 |